NCI/PDQ^® Patients: Smoking in Cancer Care (PDQ®)

National Cancer Institute
Ultima Vez Modificado: 23 de octubre del 2012

TABLE OF CONTENTS

• Introduction

• Overview

• Smoking as a Primary Risk Factor

• Poorer Treatment Response in Cancer Patients

• Smoking as a Secondary Risk Factor

• Effects of a Cancer Diagnosis on Quitting Smoking and Remaining Abstinent

• Smoking Intervention in Cancer Patients

• Treatment
  • Nicotine Replacement Therapies
  • Non-nicotine Medicines

• Changes to This Summary (10/23/2012)

• Questions or Comments About This Summary

• Get More Information From NCI

• About PDQ®

Introduction

This patient summary on smoking cessation and continued risk in cancer patients is adapted from a summary written for health professionals by cancer experts. This and other credible information about cancer treatment, screening, prevention, supportive care, and ongoing clinical trials is available from the National Cancer Institute. This brief summary describes smoking and the risks of continued smoking in adult cancer patients.

Overview

This summary briefly covers smoking as a primary risk factor for cancer, but the main focus is on the effect of smoking on cancer recurrence and diagnosis of a second primary cancer; patterns of quitting and continued smoking in cancer patients; and recommendations for cancer patients to quit smoking. Information on cancer prevention and quitting smoking in healthy people is readily available elsewhere. The information presented in this summary is related to smoking, rather than using other forms of tobacco, such as snuff or chewing tobacco.

Smoking as a Primary Risk Factor

It has been known for almost 50 years that tobacco use can be linked to cancers of the lung and head and neck. Eighty-five percent of the cases of head and neck cancer found each year are associated with tobacco use. Long-term smoking that begins before age 30 also increases the risk for developing colorectal cancer. Smoking contributes to cancer development by causing mutations in genes, impairing lung function, and decreasing the effectiveness of the immune system. See the following for more information:

• A Report of the Surgeon General: How Tobacco Smoke Causes Disease: What It Means to You
• Lung Cancer Prevention

Poorer Treatment Response in Cancer Patients

If cancer is diagnosed in a smoker, studies have found that quitting smoking will still be helpful. Even recent quitters are more likely to recover from cancer than smoking patients are. Continuing to smoke may decrease the effectiveness of treatment and may worsen treatment side effects. For example, patients who have received radiation therapy for laryngeal cancer are less likely to regain satisfactory voice quality if they continue to smoke. Also, wound healing following surgery will be more difficult if one continues to smoke. Studies have found that prostate cancer patients who keep smoking have an increased risk of earlier recurrence and death from prostate cancer. Prostate cancer patients who quit smoking for 10 years or longer, however, have about the same risk of death as nonsmokers.

Smoking as a Secondary Risk Factor

Whether a patient has a cancer that is smoking-related or nonsmoking related, he or she is at increased risk of developing a second cancer at the same or another site, if smoking is not stopped. The risk of developing a second cancer may persist for up to 20 years, even if the original cancer has been successfully treated.

Patients with oral and pharyngeal cancers who smoke also have a high rate of second primary cancers. The risk decreases significantly, however, after 5 years of not smoking.

Effects of a Cancer Diagnosis on Quitting Smoking and Remaining Abstinent

Most people who have a smoking-related cancer stop smoking or make serious efforts to quit when cancer is diagnosed. Patients who do not immediately stop smoking may be motivated to quit in the future. Some studies have shown that patients who have less intensive treatment are more likely to continue smoking, and if they quit, are more likely to start smoking again.

Smoking Intervention in Cancer Patients

Although smoking cessation research has been conducted in other patient groups, especially heart patients, few studies have involved cancer patients. These studies have shown the importance of involvement of physicians and other health care professionals in helping patients to stop smoking. The ASK, ADVISE, ASSIST, and ARRANGE model was developed in the late 1980s for health care providers and their patients who smoke. Using this model, the physician asks the patient about smoking status at every visit, advises the patient to stop smoking, assists the patient by setting a date to quit smoking, provides self-help materials, recommends use of nicotine replacement therapy (for example, the nicotine patch), and arranges for follow-up visits.

A smoking cessation study of eligible patients with cancer found that most who enrolled had a long-term smoking habit, drank alcohol several times per week, and were likely to be depressed. The study found that a smoking cessation program for such patients can be provided despite challenges, with special attention given to smokers with depression.

Not all smokers are motivated to stop smoking. Physicians should help patients become motivated to quit smoking. It is common for first time quitters to start smoking again once or many times. Quitters should be taught to anticipate stressful situations in which they will want to smoke, and to develop strategies for handling them. It may take more than a year for even motivated smokers to stop smoking. The following resources are designed to help people quit smoking:

• Consumer information about quitting smoking is available at the www.smokefree.gov Web site.
• The online Quit Guide may help patients understand reasons for smoking and the best ways to quit.
• The booklet Clearing the Air: Quit Smoking Today can be ordered at 1-800-4-CANCER (1-800-422-6237) or printed here.

Treatment

Different ways to stop smoking are effective for different patients. Some smokers can quit with the help of counseling, while others may need nicotine replacement therapy or non-nicotine medicines to help them quit. Since patients can improve their health in many ways by quitting smoking, medicines are often prescribed with careful monitoring to help them succeed.

Nicotine Replacement Therapies

Nicotine replacement therapy may help with the withdrawal symptoms that patients experience when trying to stop smoking. Nicotine products include:

• Nicotine inhalers.
• Nicotine gum.
• Nicotine lozenges.
• Nicotine patches.

A physician should be consulted before starting any form of treatment, and the following groups should take special precautions:

• Patients who are pregnant or nursing should get advice from a health care professional before using nicotine replacement products.
• Patients who continue to smoke, chew tobacco, or use snuff should not use nicotine replacement products.
• Patients aged less than 18 years and those who have the following conditions should check with a physician before using nicotine replacement products:
  • Heart disease or an irregular heartbeat.
  • High blood pressure not controlled with medicine.
  • Esophagitis or peptic ulcer disease.
  • Diabetes treated with insulin.
  • Depression or asthma treated with prescription medicines.

Non-nicotine Medicines

Non-nicotine medicines that have been studied to help people quit smoking include:

• Varenicline (also called Chantix), a drug approved by the Food and Drug Administration (FDA) for smoking cessation that acts the same way nicotine acts in the brain. This results in less craving and fewer nicotine withdrawal symptoms. In June 2011, the FDA warned that varenicline may increase the risk of cardiovascular (heart and blood vessel) adverse events in patients with cardiovascular disease. Other side effects of varenicline may include the following:
  • Problems sleeping.
  • Headaches.
  • Abnormal dreams.
  • Nausea.
  • Gas.
  • Upset stomach.
  • Constipation.
  • Feeling very tired or sleepy.

• Bupropion (also called Zyban), the only antidepressant approved by the FDA for smoking cessation.
• Fluoxetine (also called Prozac), an antidepressant shown to be effective in smoking cessation.

The FDA has directed manufacturers of bupropion and varenicline to add a boxed warning about the risk of depression, suicide, and other psychiatric events in patients who take these drugs, including:

• Psychosis.
• Hallucinations.
• Paranoia.
• Agitation.
• Anxiety.
• Panic.
• Thoughts or behaviors that are not usual for the patient.

These events have been reported in patients with or without a history of psychiatric illness. It is not known whether nicotine withdrawal is a factor in these psychiatric events. Fluoxetine has a boxed warning about an increased risk of suicide in young adults aged less than 25 years. (See the Depression and Suicide section in the PDQ® summary on Pediatric Supportive Care.)

All patients taking these drugs, especially those with a history of psychiatric illness, should be closely monitored during smoking cessation.

The FDA advises that the important health benefits of quitting smoking should be weighed against the small but serious risk of problems with the use of these drugs.

Changes to This Summary (10/23/2012)

The PDQ® cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was renamed from Smoking Cessation and Continued Risk in Cancer Patients.

Questions or Comments About This Summary

If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

Get More Information From NCI

Call 1-800-4-CANCER

For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.

Chat online

The NCI's LiveHelp online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.

Write to us

For more information from the NCI, please write to this address:

• NCI Public Inquiries Office
• Suite 3036A
• 6116 Executive Boulevard, MSC8322
• Bethesda, MD 20892-8322

Search the NCI Web site

The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.

There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.

Find Publications

The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).

About PDQ®

PDQ® is a comprehensive cancer database available on NCI's Web site.

PDQ® is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ® is available online at NCI's Web site. PDQ® is provided as a service of the NCI. The NCI is part of the National Institutes of Health, the federal government's focal point for biomedical research.

PDQ® contains cancer information summaries.

The PDQ® database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries are available in two versions. The health professional versions provide detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions provide current and accurate cancer information.

Images in the PDQ® summaries are used with permission of the author(s), artist, and/or publisher for use within the PDQ® summaries only. Permission to use images outside the context of PDQ® information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in the PDQ® summaries, along with many other cancer-related images, are available in Visuals Online, a collection of over 2,000 scientific images.

The PDQ® cancer information summaries are developed by cancer experts and reviewed regularly.

Editorial Boards made up of experts in oncology and related specialties are responsible for writing and maintaining the cancer information summaries. The summaries are reviewed regularly and changes are made as new information becomes available. The date on each summary ("Date Last Modified") indicates the time of the most recent change.

PDQ® also contains information on clinical trials.

A clinical trial is a study to answer a scientific question, such as whether one method of treating symptoms is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. Some patients have symptoms caused by cancer treatment or by the cancer itself. During supportive care clinical trials, information is collected about how well new ways to treat symptoms of cancer work. The trials also study side effects of treatment and problems that come up during or after treatment. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients who have symptoms related to cancer treatment may want to think about taking part in a clinical trial.

Listings of clinical trials are included in PDQ® and are available online at NCI's Web site. Descriptions of the trials are available in health professional and patient versions. Many cancer doctors who take part in clinical trials are also listed in PDQ®. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237).